MNPR Key Statistics, Chart & Performance
The current stock price of MNPR is 67.04 USD. In the past month the price decreased by -10.14%. In the past year, price increased by 134.9%.
MNPR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.36 | 390.15B | ||
| AMGN | AMGEN INC | 14.83 | 174.63B | ||
| GILD | GILEAD SCIENCES INC | 14.87 | 151.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.19 | 115.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.86 | 79.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 725.41 | 48.88B | ||
| INSM | INSMED INC | N/A | 34.92B | ||
| NTRA | NATERA INC | N/A | 32.83B | ||
| BIIB | BIOGEN INC | 10.65 | 26.16B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.19B | ||
| INCY | INCYTE CORP | 16.11 | 20.31B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.07 | 20.53B |
Related stock screener links
About MNPR
Company Profile
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois and currently employs 16 full-time employees. The company went IPO on 2019-12-19. The firm developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Company Info
MONOPAR THERAPEUTICS INC
1000 Skokie Blvd Ste 350
Wilmette ILLINOIS 60091 US
CEO: Chandler Robinson
Employees: 16
Phone: 18473880349
MONOPAR THERAPEUTICS INC / MNPR FAQ
What does MONOPAR THERAPEUTICS INC do?
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois and currently employs 16 full-time employees. The company went IPO on 2019-12-19. The firm developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
What is the stock price of MONOPAR THERAPEUTICS INC today?
The current stock price of MNPR is 67.04 USD. The price increased by 3.09% in the last trading session.
Does MNPR stock pay dividends?
MNPR does not pay a dividend.
What is the ChartMill technical and fundamental rating of MNPR stock?
MNPR has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is MNPR stock listed?
MNPR stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for MNPR stock?
MONOPAR THERAPEUTICS INC (MNPR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.96).
MNPR Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to MNPR. When comparing the yearly performance of all stocks, MNPR is one of the better performing stocks in the market, outperforming 93.85% of all stocks.
MNPR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MNPR. MNPR has a great financial health rating, but its profitability evaluates not so good.
MNPR Financial Highlights
Over the last trailing twelve months MNPR reported a non-GAAP Earnings per Share(EPS) of -3.96. The EPS decreased by -101.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.48% | ||
| ROE | -13.73% | ||
| Debt/Equity | 0 |
MNPR Forecast & Estimates
19 analysts have analysed MNPR and the average price target is 114.01 USD. This implies a price increase of 70.06% is expected in the next year compared to the current price of 67.04.